Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
118.62
Dollar change
-0.02
Percentage change
-0.02
%
IndexS&P 500 P/E36.32 EPS (ttm)3.27 Insider Own0.74% Shs Outstand1.73B Perf Week-0.70%
Market Cap205.83B Forward P/E23.05 EPS next Y5.15 Insider Trans-0.93% Shs Float1.72B Perf Month4.83%
Income5.70B PEG4.66 EPS next Q0.96 Inst Own77.11% Short Float0.83% Perf Quarter14.46%
Sales40.11B P/S5.13 EPS this Y4.04% Inst Trans0.27% Short Ratio2.66 Perf Half Y13.61%
Book/sh22.26 P/B5.33 EPS next Y11.39% ROA7.72% Short Interest14.29M Perf Year17.64%
Cash/sh4.19 P/C28.28 EPS next 5Y7.80% ROE15.15% 52W Range89.67 - 120.44 Perf YTD7.77%
Dividend Est.2.12 (1.78%) P/FCF40.69 EPS past 5Y19.65% ROI10.73% 52W High-1.52% Beta0.74
Dividend TTM2.08 (1.75%) Quick Ratio1.16 Sales past 5Y6.10% Gross Margin49.97% 52W Low32.28% ATR (14)1.81
Dividend Ex-DateApr 12, 2024 Current Ratio1.64 EPS Y/Y TTM-16.61% Oper. Margin16.09% RSI (14)63.18 Volatility1.29% 1.65%
Employees114000 Debt/Eq0.41 Sales Y/Y TTM-8.12% Profit Margin14.22% Recom1.81 Target Price125.20
Option/ShortYes / Yes LT Debt/Eq0.38 EPS Q/Q54.85% Payout63.81% Rel Volume0.73 Prev Close118.64
Sales Surprise0.54% EPS Surprise0.03% Sales Q/Q1.49% EarningsJan 24 BMO Avg Volume5.37M Price118.62
SMA203.01% SMA504.94% SMA20012.65% Trades Volume3,897,127 Change-0.02%
Date Action Analyst Rating Change Price Target Change
Jul-21-23Upgrade Wolfe Research Underperform → Peer Perform
May-30-23Downgrade Morgan Stanley Overweight → Equal-Weight $112
Apr-20-23Reiterated Wolfe Research Underperform $107 → $103
Apr-20-23Reiterated UBS Buy $117 → $130
Apr-20-23Reiterated Raymond James Outperform $116 → $123
Apr-20-23Reiterated JP Morgan Overweight $118 → $122
Apr-20-23Reiterated Bernstein Outperform $132 → $133
Apr-20-23Reiterated Barclays Overweight $125 → $127
Mar-29-23Initiated UBS Buy $117
Oct-26-22Initiated Mizuho Neutral $105
Today 09:45AM
Feb-28-24 05:50PM
07:51AM
05:44AM
Feb-27-24 03:04PM
05:45AM Loading…
05:45AM
Feb-26-24 02:44PM
07:10AM
04:40AM
Feb-24-24 11:22AM
Feb-23-24 11:30AM
Feb-22-24 05:50PM
Feb-21-24 07:42PM
09:04AM
03:00AM
11:21AM Loading…
Feb-20-24 11:21AM
09:00AM
Feb-18-24 06:58AM
Feb-16-24 10:19AM
Feb-14-24 03:05PM
06:31AM
Feb-13-24 06:47PM
06:31PM
06:25PM
Feb-11-24 01:06PM
06:51AM
Feb-10-24 08:30AM
Feb-09-24 09:00AM
06:45AM
Feb-08-24 08:30AM
11:11AM Loading…
Feb-07-24 11:11AM
06:01AM
05:17AM
Feb-06-24 08:30AM
Feb-05-24 09:45AM
08:25AM
Feb-04-24 08:20AM
Feb-03-24 12:21PM
07:45AM
Feb-02-24 06:22PM
12:15PM
05:03AM
Feb-01-24 03:01PM
09:00AM
07:46AM
12:06AM
Jan-31-24 09:03PM
01:13PM
10:43AM
09:00AM
Jan-30-24 04:01PM
Jan-29-24 09:00AM
Jan-26-24 06:27PM
09:40AM
Jan-25-24 05:19PM
02:26PM
02:26PM
09:38AM
09:00AM
12:21AM
Jan-24-24 04:41PM
04:23PM
03:57PM
01:22PM
01:15PM
01:08PM
11:58AM
11:05AM
10:48AM
10:36AM
10:13AM
09:30AM
08:54AM
08:40AM
07:38AM
07:38AM
07:34AM
07:30AM
07:30AM
02:46AM
Jan-22-24 08:30AM
Jan-21-24 06:17AM
Jan-20-24 02:31AM
Jan-19-24 02:19PM
05:44AM
Jan-18-24 06:00PM
01:45PM
12:10PM
09:00AM
Jan-17-24 11:01AM
06:00AM
Jan-16-24 06:58AM
05:00AM
Jan-12-24 05:50PM
09:00AM
Jan-11-24 03:25PM
02:51PM
Jan-10-24 12:01PM
11:05AM
Jan-09-24 06:00PM
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wainer Andrea FEXECUTIVE VICE PRESIDENTFeb 23Option Exercise59.9412,500749,25091,204Feb 27 06:13 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTFeb 23Sale120.0012,5001,500,00078,704Feb 27 06:13 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTJan 29Option Exercise50.8042,5002,158,95090,027Jan 31 05:30 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTJan 29Sale112.5042,5004,781,25065,027Jan 31 05:30 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTDec 14Option Exercise44.4015,000666,00080,027Dec 18 05:36 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTDec 14Sale108.0015,0001,620,00065,027Dec 18 05:36 PM
STARKS DANIEL JDirectorOct 26Sale94.0550,0004,702,5266,725,316Oct 30 04:58 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTAug 08Option Exercise38.405,000192,00075,427Aug 10 06:31 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTAug 08Sale105.0310,4001,092,29765,027Aug 10 06:31 PM
STARKS DANIEL JDirectorJul 27Sale113.7650,0005,688,1896,775,316Jul 28 05:10 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTMay 02Option Exercise47.008,226386,62278,653May 03 07:09 PM
STARKS DANIEL JDirectorMay 02Sale111.0250,0005,551,1936,825,316May 02 08:04 PM
Wainer Andrea FEXECUTIVE VICE PRESIDENTMay 02Sale110.568,226909,47270,427May 03 07:09 PM